<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358604</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL11B2</org_study_id>
    <secondary_id>COG-ANBL11B2</secondary_id>
    <secondary_id>NCI-2011-02855</secondary_id>
    <secondary_id>ANBL11B2</secondary_id>
    <nct_id>NCT01358604</nct_id>
  </id_info>
  <brief_title>Biomarkers in Samples From Young Patients With Neuroblastoma</brief_title>
  <official_title>ROR1 as a Novel Target for Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the&#xD;
      laboratory may help doctors learn more about changes that occur in DNA and identify&#xD;
      biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study studies biomarkers in samples from young patients with&#xD;
      neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.&#xD;
&#xD;
        -  To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs),&#xD;
           bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.&#xD;
&#xD;
      OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by&#xD;
      flow cytometry, western blotting, qPCR, and IHC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ROR1 is expressed on the surface of neuroblastoma cells and constitutes a suitable target for mAb therapy</measure>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with neuroblastoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosed with neuroblastoma&#xD;
&#xD;
               -  With or without N-myc amplification&#xD;
&#xD;
          -  Primary tumor samples as frozen tissue in liquid nitrogen or -80 degrees C&#xD;
&#xD;
          -  Bone marrow samples from high-risk patients as peripheral blood mononuclear cells&#xD;
             (PBMC) that have been cryopreserved with DMSO as viable cells to be used for flow&#xD;
             cytometry or slides of bone marrow that can be used for immunohistochemistry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hema, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Experimental Transplantation and Immunology Branch</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

